Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
用户k7g3AjDeE8DM
5个月前
110
10
已完结
1. 系统已在2025-03-17 11:28:36对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S2213-8587(24)00182-7
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2213858724001827
其他信息:
出版社: Elsevier BV
作者: Barbara M McGowan; Jens M Bruun; Matt Capehorn; Sue D Pedersen; Kirsi H Pietiläinen; Hanna Angelene Kudiyanur Muniraju; Maria Quiroga; Anette Varbo; David C W Lau
